Previous Article | Next Article 
Journal of Virology, October 2001, p. 9977-9982, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9977-9982.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Replacement of the Epstein-Barr Virus Plasmid with
the EBER Plasmid in Burkitt's Lymphoma Cells
Seiji
Maruo,
Asuka
Nanbo, and
Kenzo
Takada*
Department of Tumor Virology, Institute for
Genetic Medicine, Hokkaido University, N15 W7, Kita-ku, Sapporo
060-0815, Japan
Received 26 March 2001/Accepted 11 July 2001
 |
ABSTRACT |
Transfection of an Epstein-Barr virus (EBV)-encoded plasmid
containing EBER caused a substantial decrease in the level of plasmid
containing EBV in Akata and Mutu Burkitt's lymphoma (BL) lines, but
failed to do so in other BL lines. The results suggest that EBER could
replace the role of EBV, but other EBV products also play a role in the
growth of BL.
 |
TEXT |
Epstein-Barr virus (EBV) is present
in tumor cells of more than 90% of cases of Burkitt's lymphoma (BL)
in areas of endemicity in equatorial Africa and New Guinea, as well as
in tumor cells of about 10% of sporadic cases of BL occurring
worldwide (9). However, the role of EBV in the
genesis of BL is still not fully understood. To gain insight into this
problem, we have investigated the pathogenic role of EBV in BL cell
line Akata. The Akata cell line is an EBV-positive BL cell line derived
from a Japanese patient (13). It retains BL-type EBV
expression (termed type I latency) (12), which is
characterized by expression of a restricted set of latent genes,
including EBV nuclear antigen 1 (EBNA1), EBV-encoded RNAs (EBERs
[specifically EBER-1 and -2]), transcripts from the BamHI-A region (BARF0), and latent membrane protein 2A
(LMP2A). In most BL cell lines, latency is converted from type I to
type III in serial cultures, in which cells express all the EBNAs
(types 1, 2, 3A, 3B, 3C, and LP), LMPs (types 1, 2A, and 2B), EBERs, and BARF0 (9). Akata cells were originally 100% EBV
positive, but after about 2 years of in vitro cultivation, a fraction
of cells became EBV negative. We could successfully isolate
EBV-positive and -negative subclones by the limiting dilution method
(12). Comparison of EBV-positive and -negative Akata cell
clones with identical cellular backgrounds enabled us to determine
whether any phenotypic differences in cells were due to EBV. Using this system, we verified that, in Akata cells, EBV was necessary for the
malignant phenotype, resistance to apoptosis, and upregulated expression of bcl-2 oncoprotein (7, 12). We also
demonstrated that EBER was responsible for these phenotypes
(6). Similar results have been reported by other groups
(2, 10, 11, 14). We further demonstrated that EBER induces
expression of cellular interleukin-10 (IL-10) in BL cells, including
Akata and Mutu cells, and that the induced IL-10 acts as an autocrine
growth factor for BL (5). These results clearly
demonstrate that EBER is very important for the growth and malignant
conversion of BL cells.
EBV is maintained as an episome in EBV-infected cells. It has been
reported that the system of plasmid maintenance operated by binding of
EBNA1 to the replication origin of the plasmid that contains EBV
(oriP) (15) is not perfect, and 4% of cells
per generation lose EBV plasmids (4). If so,
theoretically, the EBV-negative population should increase during
cultivation, although we have not seen such a phenomenon in most
EBV-infected cultures, with a few exceptions, including Akata cell
culture. The most probable explanation is that EBV-infected cell lines
depend on the presence of EBV for their survival. Accumulation of
mutations of cellular genes during cultivation of Akata cells made some fraction of the cells independent of EBV under ordinary culture conditions, and thus, we could isolate EBV-negative subclones.
Based on this background, in this study, we examined whether EBER could
replace the role of EBV in Akata cells. As described above,
EBV-negative cells appeared in an Akata cell culture that had been
continuously cultivated in vitro for about 2 years. From that culture,
we could isolate EBV-negative subclones by the limiting dilution
method. In contrast, an early culture of the Akata cell line, referred
to as Akata-EC, maintained the EBV plasmid stably. Several attempts
failed to isolate EBV-negative subclones from Akata-EC cells by
limiting dilution. These results suggest that survival of Akata-EC
cells depends on EBV infection. Therefore, we used Akata-EC cells to
test whether EBER could be substituted for EBV.
EBER1 and -2 open reading frames are located at bp 6628 to 6796 and
6958 to 7129, respectively, on the EcoRI K fragment of Akata
EBV DNA, which corresponds to the EcoRI-J fragment of B95-8 EBV DNA (1). Since the plasmid that contained a single
copy of EBER could not induce levels of EBER expression in transfected cells equivalent to those in EBV-infected cells, we used the plasmid that contained 10 tandem repeats of the EBER1 and -2 subfragment (SacI-EcoRI fragment, bp 6297 to 7325) from the
EcoRI-K fragment of Akata EBV DNA and a neomycin resistance
(Neor) gene driven by the simian virus 40 promoter (7). By electroporation, Akata-EC cells (5 × 106) were transfected with either the
EBER-containing plasmid or the control plasmid
(pNeor), which contained a neomycin resistance
gene driven by the simian virus 40 promoter. After 2 days of
transfection, cells were transferred to 96-well, flat-bottom plates at
5,000 cells per well in complete culture medium containing 1.5 mg of
G418 per ml (GIBCO). Half of the medium was changed every 6 days until
colonies emerged. Eight Neor-transfected clones
and 14 EBER-transfected clones were cultured in selective medium for 1 year.
These clones were examined by Southern blot analysis for the existence
of EBV and EBER plasmids. Ten micrograms of cellular DNA was digested
with the EcoRI restriction enzyme, separated in a 0.8%
agarose gel, blotted onto Hybond N+ nylon
membranes (Amersham), and hybridized with a
32P-labeled EBER probe. As shown in Fig.
1A, all
Neor-transfected Akata-EC clones maintained the
EBV-containing plasmid, as illustrated by the presence of a 3.0-kb
band. The intensities of the bands were similar among the clones and
did not change even after 1 year of culture, indicting that the EBV
plasmid is stably maintained in Akata EC cells. In contrast, the
intensity of the 3.0-kb band varied considerably among EBER-transfected clones. The 3.0-kb band was undetectable in one clone (clone 3) after 3 months of culture and in four clones (clones 3, 8, 9, and 13) after 1 year of culture.


View larger version (141K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Detection of DNA from the EBV plasmid and
transfected EBER DNA in Akata-EC cell clones. Akata-EC cells were
transfected with the EBER plasmid carrying the neomycin resistance gene
or a Neor plasmid (as a control) and cultured in selective
medium containing 1.5 mg of G418 per ml. G418-resistant cell clones
were isolated and continuously cultivated for 1 year. Cellular DNA (10 µg) was isolated from each cell clone at 3 months and 1 year of
culture, digested with EcoRI restriction endonuclease,
blotted onto a nylon membrane, and hybridized with a
32P-labeled EBER probe. The 3.0-kbp band is DNA from the
EBV plasmid, and the 1.1-kbp band is transfected EBER DNA. Photos of
ethidium bromide-stained agarose gel are also shown. (B) EBNA
expression in EBER- and Neor-transfected Akata EC cell
clones. EBNA was stained in the anticomplement immunofluorescence
assay.
|
|
Expression of EBNA in Neor- or
EBER-transfected AkataEC clones was examined by
immunofluorescence assay. Cell smears on glass slides were fixed in
acetone-methanol (1:1) for 2 min and sequentially incubated with a
standard EBNA-positive human serum containing complement and
fluorescein isothiocyanate-conjugated antihuman C3c (Dako). The results
are summarized in Table 1. All
Neor-transfected clones were virtually 100%
positive for EBNA at any culture time. In contrast, the frequency of
EBNA-positive cells varied considerably from 0% to >95% among
EBER-transfected clones. There was a good correlation between the
intensity of the band of the EBV plasmid in Southern blot analysis
(Fig. 1A) and the frequency of EBNA-positive cells. Figure 1B shows the
EBNA staining of representative clones. In summary, these results
indicate that transfection of the EBER gene causes a loss or decrease
of EBV plasmid in Akata-EC cells.
Although about half of EBER-transfected Akata-EC clones
lost the EBV genome, the rest retained the virus
like before after a year of culture. This might have been due to the
low expression of EBER from the transfected EBER-containing plasmid.
However, we cannot determine EBER expression from the transfected EBER plasmid in EBV-positive cells, because we cannot discriminate EBER RNA
transcribed from the endogenous EBV genome from that transcribed from
the transfected EBER plasmid. Therefore, we transfected EBER plasmid
into EBV-negative Akata cells. After transfection, cells were
transferred into 96-well plates and incubated in selective medium
containing 1 mg of G418 per ml. Twenty-seven drug-resistant cell clones
were randomly selected and examined for the expression of EBER by
reverse transcription-PCR (RT-PCR), as described previously (6). As shown in Fig. 2, six
clones expressed EBER at a level equivalent to or higher than that of
EBV-positive Akata cells, but in nine clones, EBER was undetectable,
and the remaining clones expressed it at a lower level. In contrast,
four Akata-EC clones (clones 3, 8, 9, and 13), from which EBV
plasmid was lost after EBER transfection (Table 1), expressed EBER at a
level equivalent to that of EBV-positive Akata cells. These results
suggested that clonal variation in EBER expression could explain why
about half of EBER-transfected Akata-EC cell clones retained EBV
plasmid.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 2.
EBER expression in EBER-transfected Akata cell clones.
EBER expression was determined by the RT-PCR method as described
previously (6). (A) Determination of EBER expression by
using different amounts of cDNA as templates. cDNA (100 ng) from
EBV-positive Akata cells was diluted twofold and used as a
template for PCR. (B) EBER expression in EBER-transfected
EBV-negative Akata cell clones. One hundred nanograms of cDNA was
used as a template for PCR. (C) EBER expression in EBER-transfected
Akata-EC cell clones from which the EBV plasmid was lost. One hundred
nanograms of cDNA was used as a template for PCR.
|
|
Besides Akata cells, we examined other type I BL lines, such as Mutu I
(3), Oku I, Sav I, and Kem I, to see whether EBER could
replace the EBV plasmid in these cell lines. Southern blot analysis
indicated that the level of the EBV plasmid decreased in four of nine
Mutu I cell clones that were transfected with the EBER plasmid (Fig.
3A). The
immunofluorescence assay indicated that in at least one clone (clone
3), EBNA positivity decreased to 40%, while all
Neor-transfected clones retained 100% EBNA
positivity (Fig. 3B). On the other hand, in the Oku I, Sav I, and Kem I
cell lines, transfection of EBER plasmid did not influence the copy
number of the EBV plasmid (data not shown).


View larger version (97K):
[in this window]
[in a new window]
|
FIG. 3.
Detection of DNA from the EBV plasmid and
transfected EBER DNA in Mutu I cell clones. Akata-EC cells were
transfected with EBER-containing plasmid carrying the neomycin
resistance gene or a Neor plasmid (as a control) and
cultured in selective medium containing 1.5 mg of G418 per ml.
G418-resistant cell clones were isolated and cultivated for 1 year.
Cellular DNA (10 µg) was isolated from each cell clone at 1 year of
culture, digested with EcoRI restriction endonuclease,
blotted onto a nylon membrane, and hybridized with
32P-labeled EBER probe. The 3.0-kbp band is DNA from the
EBV plasmid, and the 1.1-kbp band is transfected EBER DNA. Photos of
ethidium bromide-stained agarose gel are also shown. (B) EBNA
expression in EBER-transfected and Neor-transfected Mutu I
cell clones. EBNA was stained in the anticomplement immunofluorescence
assay.
|
|
Finally, we studied whether genome loss reflected some inhibitory
effect of EBER on oriP function. EBV-negative Akata cells were
transfected with a plasmid, EBO, containing oriP, the EBNA1 gene, and the Neor gene (8) and
maintained in medium containing G418. G418-resistant cell clones were
then isolated. These cell clones carrying the plasmid containing
oriP stably were transfected with the EBER plasmid or the
Neor gene. Seven days after transfection, cells
were harvested for detection of oriP plasmid DNA. Southern
blot analysis indicated that there was no difference in the intensities
of the oriP DNA bands between EBER- and
Neor-transfected cells (Fig.
4). The results indicate that EBER
does not influence retention of the oriP-containing plasmid.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of EBER expression on retention of
oriP-containing plasmid. EBV-negative Akata cell clones
stably carrying the oriP-containing plasmid EBO were transfected with
the Neor or EBER plasmid. Seven days after transfection,
cells were harvested for detection of oriP DNA. Cellular
DNA (10 µg) was digested with HindIII restriction
endonuclease, blotted onto a nylon membrane, and hybridized with a
32P-labeled EBO probe.
|
|
In the present study, we have demonstrated that EBER plasmid could
replace the EBV plasmid in at least in two type I BL cell lines, Akata
and Mutu I. These results are consistent with our previous reports that
EBER is important for the growth and malignant phenotypes of type I BL
cell lines (5, 6). However, we failed to replace EBV
plasmid with the EBER plasmid in the other three type I BL cell lines.
These results suggest that other EBV gene products play a role in the
growth of BL cells.
 |
ACKNOWLEDGMENTS |
We thank J. Sample for the Mutu I, Oku I, Kem I, and Sav I cell
lines; K. Adachi for technical assistance; and K. Inoue for help with
preparing the manuscript.
This work was supported by grants-in-aid from the Ministry of
Education, Science, Sports, and Culture, Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing Address: Department of
Tumor Virology, Institute for Genetic Medicine, Hokkaido University, N15 W7, Kita-ku, Sapporo 060-0815, Japan. Phone: 81-11-706-5071. Fax:
81-11-717-1128. E-mail: kentaka{at}med.hokudai.ac.jp.
 |
REFERENCES |
| 1.
|
Baer, R.,
A. T. Bankier,
M. D. Biggin,
P. L. Deininger,
P. J. Farrell,
T. J. Gibson,
C. Hutful,
G. S. Hudson,
S. C. Satchwell,
C. Seguin,
P. S. Tuffnell, and B. G. Barrell.
1984.
DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Nature (London)
310:207-211[CrossRef][Medline].
|
| 2.
|
Chodosh, J.,
V. P. Holder,
Y. Gan,
A. Belgaumi,
J. Sample, and J. W. Sixbey.
1998.
Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype.
J. Infect. Dis.
177:1194-1201[Medline].
|
| 3.
|
Gregory, C. D.,
M. Rowe, and A. B. Rickinson.
1990.
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
J. Gen. Virol.
71:1481-1495[Abstract/Free Full Text].
|
| 4.
|
Kirchmaier, A. L., and B. Sugden.
1995.
Plasmid maintenance of derivatives of oriP of Epstein-Barr virus.
J. Virol.
69:1280-1283[Abstract].
|
| 5.
|
Kitagawa, N.,
M. Goto,
K. Kurozumi,
S. Maruo,
M. Fukayama,
T. Naoe,
M. Yasukawa,
K. Hino,
T. Suzuki,
S. Todo, and K. Takada.
2000.
Epstein-Barr virus-encoded poly (A) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.
EMBO J.
19:6742-6750[CrossRef][Medline].
|
| 6.
|
Komano, J.,
S. Maruo,
K. Kurozumi,
T. Oda, and K. Takada.
1999.
Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata.
J. Virol.
73:9827-9831[Abstract/Free Full Text].
|
| 7.
|
Komano, J.,
M. Sugiura, and K. Takada.
1998.
Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
J. Virol.
72:9150-9156[Abstract/Free Full Text].
|
| 8.
|
Margolskee, R. F.,
P. Kavathas, and P. Berg.
1988.
Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells.
Mol. Cell. Biol.
8:2837-2847[Abstract/Free Full Text].
|
| 9.
|
Rickinson, A. B., and E. Kieff.
1996.
Epstein-Barr virus, p. 2397-2446.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 10.
|
Ruf, I. K.,
P. W. Rhyne,
H. Yang,
C. M. Borza,
L. M. Hutt-Fletcher,
J. L. Cleveland, and J. T. Sample.
1999.
Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.
Mol. Cell. Biol.
19:1651-1660[Abstract/Free Full Text].
|
| 11.
|
Ruf, I. K.,
P. W. Rhyne,
C. Yang,
J. L. Cleveland, and J. T. Sample.
2000.
Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.
J. Virol.
74:10223-10228[Abstract/Free Full Text].
|
| 12.
|
Shimizu, N.,
A. Tanabe-Tochikura,
Y. Kuroiwa, and K. Takada.
1994.
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.
J. Virol.
68:6069-6073[Abstract/Free Full Text].
|
| 13.
|
Takada, K.,
K. Horinouchi,
Y. Ono,
T. Aya,
T. Osato,
M. Takahashi, and S. Hayasaka.
1991.
An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA.
Virus Genes
5:147-156[CrossRef][Medline].
|
| 14.
|
Yamamoto, N.,
T. Takizawa,
Y. Iwanaga,
N. Shimizu, and N. Yamamoto.
2000.
Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs.
FEBS Lett.
484:153-158[CrossRef][Medline].
|
| 15.
|
Yates, J. L.,
N. Warren,
D. Reisman, and B. Sugden.
1984.
A cis-acting element from the Epstein-Barr virus genome that permits stable replication of recombinant plasmids in latently infected cells.
Proc. Natl. Acad. Sci. USA
81:3806-3810[Abstract/Free Full Text].
|
Journal of Virology, October 2001, p. 9977-9982, Vol. 75, No. 20
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.20.9977-9982.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sisk, E. A., Bradford, C. R., Carey, T. E., Paulino, A., Robertson, E.
(2003). Epstein-Barr Virus Detected in a Head and Neck Squamous Cell Carcinoma Cell Line Derived From an Immunocompromised Patient. Arch Otolaryngol Head Neck Surg
129: 1115-1124
[Abstract]
[Full Text]